WVP
ABEO icon

Worth Venture Partners’s Abeona Therapeutics ABEO Stock Holding History

Worth Venture Partners’s Portfolio ABEO Stock Details ABEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-196,439
Closed -$984K – 63
2023
Q4 		$984K Sell
196,439
-84,841
-30% -$373K 0.53% 61
2023
Q3 		$1.18M Buy
281,280
+121,969
+77% +$462K 0.7% 49
2023
Q2 		$642K Sell
159,311
-1,200
-0.7% -$4.2K 0.35% 65
2023
Q1 		$453K Hold
160,511
– – 0.22% 89
2022
Q4 		$494K Buy
160,511
+125,738
+362% +$470K 0.29% 79
2022
Q3 		$106K Buy
34,773
+33,382
+2,400% +$138K 0.06% 131
2022
Q2 		$169K Sell
1,391
-48,400
-97% -$245K 0.1% 116
2022
Q1 		$392K Buy
49,791
+4,300
+9% +$29.5K 0.18% 92
2021
Q4 		$383K Buy
+45,491
New +$836K 0.19% 90

Other funds holding ABEO

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
WSL
Western Standard LLC Los Angeles, California $190M AUM 40.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $24B AUM 37.67% 1-Year Est. Return

Worth Venture Partners's ABEO Position: Q1 2024 in Review

Worth Venture Partners sold out of Abeona Therapeutics (ABEO) in Q1 2024, closing a stake of 196,439 shares — an estimated $984K sold.

Worth Venture Partners first reported a position in ABEO in Q4 2021 and held it in 9 quarters. The position peaked at $1.18M in Q3 2023. 56 funds tracked by Wall St. Rank hold ABEO as of Q1 2024.

  • Worth Venture Partners reported no remaining Abeona Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Worth Venture Partners sold 196,439 Abeona Therapeutics shares in Q1 2024, an estimated $984K.
  • Worth Venture Partners first reported a position in Abeona Therapeutics in Q4 2021 and held it in 9 quarters.
  • Worth Venture Partners's Abeona Therapeutics position peaked at $1.18M in Q3 2023.
  • 56 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q1 2024.

Based on Worth Venture Partners's 13F filing for Q1 2024, filed 13 May 2024.